Pharmafile Logo
Pharmafocus logo
Advanced Search

NICE

Showing 15 posts of 866 posts found.

Zelboraf image

NICE still minded not to recommend Zelboraf

August 9, 2012
Sales and Marketing BMS, NICE, QALY, Yervoy, Zelboraf

NICE is asking Roche for more information about its melanoma pill Zelboraf, saying it is still too expensive and its …

News
Nicholson image

Nicholson to end NHS black listing of drugs

August 9, 2012
Sales and Marketing IHW, NHS, NICE, Sir David Nicholson, formulary

The chief executive of the NHS is looking to stamp out black listing of NICE-approved medicines. In a letter to …

News

GSK’s Votrient gains new licence

August 8, 2012
Sales and Marketing GSK, NICE, Votrient, soft cell sarcoma

GlaxoSmithKline has gained a new European licence for its cancer pill Votrient adding to its renal cell carcinoma licence. The …

News
Rawlins image

Sue NHS to ensure access to drugs, says NICE chief

August 6, 2012
Lucentis, NICE, Ozurdex, judicial review, market access, ophthamology

 The chairman of NICE is advising campaigners to sue NHS bodies that block a treatment recommended by the watchdog.In a …

News
ABPI image

ABPI outlines vision for drug pricing reform

August 3, 2012
Sales and Marketing ABPI, NICE, PPRS, VBP, Whitehead, value-based pricing

The ABPI has set out what it wants to see from the new drug pricing system in the UK. Negotiations …

News
Xarelto image

NICE yes for Xarelto to treat blood clots

July 25, 2012
Sales and Marketing Bayer, DVT, NHS, NICE, Pradaxa, VTE, Xarelto

NICE is recommending Bayer’s Xarelto (rivaroxaban) for the treatment and prevention of deep vein thrombosis (DVT). The watchdog said in …

News
NICE image

NICE to assess high cost drugs for rare conditions

July 24, 2012
Sales and Marketing AGNSS, NHS, NICE, Rawlins, rare conditions

NICE is to be responsible next year for assessing high cost drugs for people with rare medical conditions as part …

News
Avastin pack shot

NICE no for Avastin in breast cancer

July 6, 2012
Sales and Marketing NICE, Roche, avastin, breast cancer, rejection

NICE has decided once again not to recommend Roche’s Avastin on the NHS for the first line treatment of metastatic …

News

Astellas submits new prostate cancer drug to EMA

June 28, 2012
Research and Development, Sales and Marketing Astellas, EMA, Medivation, NICE, Zytiga, enzalutamide

Astellas has submitted its investigational prostate cancer drug enzalutamide to the European Medicines Agency. Enzalutamide is a once-daily pill that works …

News
Tarceva image

NICE final yes for Zytiga and Tarceva

June 27, 2012
Sales and Marketing Janssen, NHS, NICE, NSCLC, Roche, Tarceva, Zytiga

In final guidance published today, NICE is recommending two new drugs for patients with prostate and lung cancer. Janssen’s Zytiga …

News

MPs find NHS bodies still blocking treatments

June 25, 2012
Sales and Marketing CCGs, MPs, NHS, NICE, PCTs, Pfizer, viagra

The Labour party has uncovered new restrictions to treatments and drugs in the NHS, which it says is hurting patients …

News

The European Medicines Group: focused on UK market access

June 25, 2012
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, EMG, NICE, VBP, market access

Maintaining a dialogue with government, NHS organisations and other stakeholder groups is essential for pharma companies in the UK, and …

Feature
Zytiga image

Janssen looks to broaden Zytiga licence

June 18, 2012
Sales and Marketing Cancer, Janssen, NICE, Provenge, Zytiga, prostate

Janssen is looking to broaden the licence for its prostate cancer pill Zytiga. Zytiga currently has a US and European …

News
NICE app

NICE launches new BNF prescribing app

June 15, 2012
Medical Communications, Sales and Marketing BNF, NICE, app, digital, pharma

NICE has launched a new app that allows users to search all medicines listed in the British National Formulary. The …

News
Zelboraf image

Roche’s Zelboraf rejected by NICE

June 15, 2012
Sales and Marketing Cancer, Dillon, NICE, Roche, Zelboraf, melanoma

NICE is not recommending Roche’s targeted melanoma pill Zelboraf because of its high cost and uncertainties over its survival benefit. …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026